Skip to main content
Advertisement

< Back to Article

Fig 1.

Study flow diagram.

O: Objective outcomes; S: Subjective outcomes.

More »

Fig 1 Expand

Table 1.

Main characteristics of included and ongoing studies.

More »

Table 1 Expand

Fig 2.

Risk of bias item for each included study.

A) Random sequence generation (selection bias), (B) allocation concealment (selection bias), (C) blinding of participants and personnel (performance bias), (D) blinding of outcome assessment (detection bias), (E) incomplete outcome data (attrition bias), (F) selective reporting (reporting bias), (G) other bias O: Objective outcomes, S: subjective outcomes.

More »

Fig 2 Expand

Table 2.

Summary of findings: Benznidazole fixed vs adjusted dose.

More »

Table 2 Expand

Fig 3.

Positive serology at one year.

A) Random sequence generation (selection bias), (B) allocation concealment (selection bias), (C) blinding of participants and personnel (performance bias), (D) blinding of outcome assessment (detection bias), (E) incomplete outcome data (attrition bias), (F) selective reporting (reporting bias), (G) other bias.

More »

Fig 3 Expand

Table 3.

Summary of findings: Benznidazole versus placebo.

More »

Table 3 Expand

Fig 4.

Positive PCR at one year.

A) Random sequence generation (selection bias), (B) allocation concealment (selection bias), (C) blinding of participants and personnel (performance bias), (D) blinding of outcome assessment (detection bias), (E) incomplete outcome data (attrition bias), (F) selective reporting (reporting bias), (G) other bias.

More »

Fig 4 Expand

Fig 5.

Drug discontinuation.

A) Random sequence generation (selection bias), (B) allocation concealment (selection bias), (C) blinding of participants and personnel (performance bias), (D) blinding of outcome assessment (detection bias), (E) incomplete outcome data (attrition bias), (F) selective reporting (reporting bias), (G) other bias.

More »

Fig 5 Expand

Fig 6.

Peripheral neuropathy.

A) Random sequence generation (selection bias), (B) allocation concealment (selection bias), (C) blinding of participants and personnel (performance bias), (D) blinding of outcome assessment (detection bias), (E) incomplete outcome data (attrition bias), (F) selective reporting (reporting bias), (G) other bias.

More »

Fig 6 Expand

Fig 7.

Mild rash.

(1) Bendita 20117 (Maculo-papular rash + papular rash + erythema. A) Random sequence generation (selection bias), (B) allocation concealment (selection bias), (C) blinding of participants and personnel (performance bias), (D) blinding of outcome assessment (detection bias), (E) incomplete outcome data (attrition bias), (F) selective reporting (reporting bias), (G) other bias.

More »

Fig 7 Expand